Pyridostigmine potentiates l-dopa- but not arginine- and galanin-induced growth hormone secretion in children

Ezio Ghigo, Jaele Bellone, Eliseo Imperiale, Emanuela Aivat, Enrico Mazza, Maria Rosa Valetta, Gian Mario Beffano, Marco Cappa, Sandro Loche, Carlo De Sanctis, Eugenio E. Müller, Franco Camanni

Research output: Contribution to journalArticlepeer-review


The coadministration of growth hormone (GH) secretagogues can provide insight into the neuroregulation of GH secretion. The GH response to L-dopa (125, 250 and 500 mg orally for body weights <15 kg, between 15 and 30 kg and > 30 kg, respectively), arginine (Arg; 0.5 g/kg infused intravenously over 30 min) and galanin (GAL; 15 ug/kg infused intravenously over 60 min) when administered alone or combined with pyridostigmine (PD; 60 mg orally), a cholinergic agonist that likely acts via inhibition of endogenous somatostatin secretion, was studied in children with familial short stature. The GH-releasing effect of PD was also evaluated. In 8 children, PD and L-dopa when administered alone induced an equivalent GH rise (area under the response curve, mean ± SEM: 241.4 ± 31.1 vs. 202.9 ± 38.6 μg/l/h) while their coadministration had an additive effect (435.4 ± 41.4 μg/I/h; p

Original languageEnglish
Pages (from-to)42-45
Number of pages4
Issue number1
Publication statusPublished - 1990


  • Arginine
  • Children
  • Galanin
  • Growth hormone
  • L-Dopa
  • Pyridostigmine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Cellular and Molecular Neuroscience
  • Endocrine and Autonomic Systems
  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Pyridostigmine potentiates l-dopa- but not arginine- and galanin-induced growth hormone secretion in children'. Together they form a unique fingerprint.

Cite this